| Outcome Measures: |
Primary: Phase I: Occurence of adverse events (AEs), To evaluate the safety of AZD7760 administered as a single intravenous (IV) Dose A, B, or C., Day 1 to Day 181|Phase I: Occurence of medically-attended adverse events (MAAEs), serious adverse events (SAEs), and adverse events of special interest (AESIs), To evaluate the safety of AZD7760 administered as a single IV Dose A, B, or C., Day 1 to Day 361|Phase IIa: Occurrence of AEs, MAAEs, SAEs, and AESIs, To evaluate the safety of AZD7760 compared with placebo as: * A single IV dose (at Day 1) of Dose D followed by placebo (at Day 91) * 2 IV doses (at Day 1 and Day 91) of Dose E, Day 1 to Day 181 | Secondary: Phase I: Maximum observed plasma (peak) drug concentration (Cmax), To characterize the pharmacokinetics (PK) of AZD7760 in serum., Day 1 to Day 361|Phase I: Time to reach peak or maximum observed concentration following drug administration (tmax), To characterize the PK of AZD7760 in serum., Day 1 to Day 361|Phase I: Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t1/2λz), To characterize the PK of AZD7760 in serum., Day 1 to Day 361|Phase I: Area under the plasma concentration-curve from zero to the last quantifiable concentration (AUClast), To characterize the PK of AZD7760 in serum., Day 1 to Day 361|Phase I: Area under plasma concentration-time curve from zero extrapolated to infinity (AUCinf), To characterize the PK of AZD7760 in serum., Day 1 to Day 361|Phase I: Apparent volume of distribution at steady state (Vss), To characterize the PK of AZD7760 in serum., Day 1 to Day 361|Phase I: Apparent volume of distribution at the terminal phase (Vz), To characterize the PK of AZD7760 in serum., Day 1 to Day 361|Phase I: Incidence of ADA, To evaluate ADA responses to AZD7760 in serum., Day 1 to Day 361|Phase IIa: Cmax, To characterize the serum PK profiles of AZD7760 administered as: * A single IV dose (at Day 1) of Dose D followed by placebo (at Day 91) * 2 IV doses (at Day 1 and Day 91) of Dose E, Day 181 to Day 451|Phase IIa: tmax, To characterize the serum PK profiles of AZD7760 administered as: * A single IV dose (at Day 1) of Dose D followed by placebo (at Day 91) * 2 IV doses (at Day 1 and Day 91) of Dose E, Day 181 to Day 451|Phase IIa: t1/2λz, To characterize the serum PK profiles of AZD7760 administered as: * A single IV dose (at Day 1) of Dose D followed by placebo (at Day 91) * 2 IV doses (at Day 1 and Day 91) of Dose E, Day 181 to Day 451|Phase IIa: AUClast, To characterize the serum PK profiles of AZD7760 administered as: * A single IV dose (at Day 1) of Dose D followed by placebo (at Day 91) * 2 IV doses (at Day 1 and Day 91) of Dose E, Day 181 to Day 451|Phase IIa: AUCinf, To characterize the serum PK profiles of AZD7760 administered as: * A single IV dose (at Day 1) of Dose D followed by placebo (at Day 91) * 2 IV doses (at Day 1 and Day 91) of Dose E, Day 181 to Day 451|Phase IIa: Vss, To characterize the serum PK profiles of AZD7760 administered as: * A single IV dose (at Day 1) of Dose D followed by placebo (at Day 91) * 2 IV doses (at Day 1 and Day 91) of Dose E, Day 181 to Day 451|Phase IIa: Vz, To characterize the serum PK profiles of AZD7760 administered as: * A single IV dose (at Day 1) of Dose D followed by placebo (at Day 91) * 2 IV doses (at Day 1 and Day 91) of Dose E, Day 181 to Day 451|Phase IIa: Incidence of anti-drug antibodies (ADAs) to AZD7760 in serum, To evaluate ADA responses to AZD7760 administered as: * A single IV dose (at Day 1) of Dose D followed by placebo (at Day 91) * 2 IV doses (at Day 1 and Day 91) of Dose E, Day 181 to Day 451|Phase IIa: Occurrence of AEs, To evaluate the safety to Day 181 of AZD7760 administered as: * A single IV dose (at Day 1) of Dose D followed by placebo (at Day 91) * 2 IV doses (at Day 1 and Day 91) of Dose E, Day 1 to Day 181|Phase IIa: Occurrence of MAAEs, SAEs, and AESIs, To evaluate the safety to Day 451 of AZD7760 administered as: * A single IV dose (at Day 1) of Dose D followed by placebo (at Day 91) * 2 IV doses (at Day 1 and Day 91) of Dose E, Day 1 to Day 451
|
| Locations: |
Research Site, Glendale, California, 91206, United States|Research Site, Los Angeles, California, 90027, United States|Research Site, Tarzana, California, 91356, United States|Research Site, Baltimore, Maryland, 21225, United States|Research Site, Albuquerque, New Mexico, 87109, United States
|
